Precision medicine becomes reality-tumor type-agnostic therapy

Cancer Communications
Li Yan, Wei Zhang

Abstract

Precision medicine just witnessed two breakthroughs in oncology in 2017. Pembrolizumab (Keytruda), Merck's anti-programmed cell death-1 (PD-1) monoclonal antibody (mAb), received accelerated approval in May 2017 by the US Food and Drug Administration for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors that have been identified as having microsatellite instability-high (MSI-H) or deficient DNA mismatch repair (dMMR). Shortly after, nivolumab (Opdivo), Bristol-Myers Squibb's anti-PD-1 mAb, gained an accelerated approval in August 2017 for adult and pediatric patients with MSI-H or dMMR metastatic colorectal cancer that has progressed after standard chemotherapy. These regulatory approvals marked an important milestone that a cancer treatment may be approved based on a common biomarker rather than the anatomic location in the body where the tumor originated, and therefore established a precedent for tumor type-agnostic therapy. In the 2017 American Society for Clinical Oncology annual meeting, larotrectinib (LOXO-101), Loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases (TRK), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors w...Continue Reading

References

Feb 10, 2010·Nature Reviews. Clinical Oncology·Eduardo Vilar, Stephen B Gruber
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerSuzanne L Topalian
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Nov 22, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Evan J LipsonSuzanne L Topalian
Dec 7, 2013·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Madhuri HegdeUNKNOWN Working Group of the American College of Medical Genetics and Genomics (ACMG) Laboratory Quality Assurance Committee
Jun 2, 2015·The New England Journal of Medicine·Dung T LeLuis A Diaz
Aug 20, 2015·The New England Journal of Medicine·David M HymanJosé Baselga
Feb 18, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jonathan C DudleyJames R Eshleman
Nov 1, 2016·Nature Medicine·Ronald J HauseStephen J Salipante
Feb 9, 2018·Nature·David M HymanDavid B Solit
Feb 22, 2018·The New England Journal of Medicine·Alexander DrilonDavid M Hyman
Mar 11, 2018·The Oncologist·Dmitry Ratner, Jochen K Lennerz

❮ Previous
Next ❯

Citations

Apr 5, 2019·The British Journal of Surgery·I S ReynoldsJ P Burke
Aug 25, 2019·Cancers·Yoshitaro ShindoHiroaki Nagano
Aug 14, 2019·The Journal of Clinical Investigation·Zining WangXiaojun Xia
Oct 28, 2019·Expert Review of Gastroenterology & Hepatology·Shi-Dong LuJian-Hong Zhong
Nov 5, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aurelien MarabelleLuis A Diaz
Oct 3, 2019·Current Opinion in Neurology·Marta Penas-PradoMark R Gilbert
Jan 13, 2019·The Oncologist·Katharine E H ThomasRobert A Ramirez
Aug 26, 2020·Cancer Communications·Michael Mints, Itay Tirosh
Jul 25, 2019·The Cancer Journal·Marina Baretti, Nilofer Saba Azad
Sep 19, 2020·Cancer Communications·Feng WangRui-Hua Xu
May 30, 2019·Clinical & Translational Immunology·Michael P BrownTessa Gargett
Nov 5, 2019·Thoracic Cancer·Tai-Ze YuanChao-Nan Qian
Mar 3, 2020·Frontiers in Immunology·Sara SaabHumam Kadara
Mar 27, 2019·Critical Care : the Official Journal of the Critical Care Forum·Nadir Yehya
Jul 10, 2019·Journal of Personalized Medicine·Anantbhushan RanadeDadasaheb Akolkar
Aug 20, 2020·Breast Cancer Research : BCR·Xue ChaoJingping Yun
Nov 21, 2020·Clinical Journal of Oncology Nursing·Suzanne M Mahon
Nov 21, 2020·Clinical Journal of Oncology Nursing·Mary L Schmitt
Jan 31, 2020·Molecular Cancer Research : MCR·Kelly C S OliveiraDanielle Queiroz Calcagno
Sep 18, 2020·Case Reports in Women's Health·William BoyleRaji Ganesan
Feb 6, 2021·Endocrine·Anna KoumarianouKrystallenia I Alexandraki
Mar 7, 2021·Pharmaceuticals·Ottavia BernocchiDaniele Generali
Mar 12, 2021·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Jill M Kolesar, Lee C Vermeulen

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
proximity ligation

Clinical Trials Mentioned

NCT02122913
NCT02637687
NCT02576431

Software Mentioned

Keytruda
MSI Analysis System
IMPACT

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Sequencing

Several sequencing approaches are employed to understand and examine tumor development and progression. These include whole genome as well as RNA sequencing. Here is the latest research on cancer sequencing.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.